Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Introduction : In the past decade, the combination of high-dose melphalan (MEL) and auto-hematopoietic stem cell transplantation (auto-HCT) with novel agents substantially improved the outcomes in younger patients with multiple myeloma. However, the safety and efficacy of auto-HCT in patients aged ≥...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.3437-3437
Main Authors: Mizuno, Shohei, Kawamura, Koji, Hanamura, Ichiro, Sunami, Kazutaka, Mori, Takehiko, Nakamura, Fumihiko, Iida, Shinsuke, Nakazawa, Hideyuki, Makita, Masanori, Kako, Shinichi, Sawa, Masashi, Ueda, Yasunori, Takahashi, Hiroyuki, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, Takamatsu, Hiroyuki, Takami, Akiyoshi
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction : In the past decade, the combination of high-dose melphalan (MEL) and auto-hematopoietic stem cell transplantation (auto-HCT) with novel agents substantially improved the outcomes in younger patients with multiple myeloma. However, the safety and efficacy of auto-HCT in patients aged ≥65 years remain uncertain. Large clinical trials evaluating the role of auto-HCT in multiple myeloma mostly included patients aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-109905